TechBio company BioCurie was awarded up to $9.3 million in funding from the Advanced Research Projects Agency for Health (ARPA-H) to accelerate the development of scalable, data-driven genomic medicine production.
Under the ARPA-H award, BioCurie will design, build and validate an AI-powered digital platform that replaces trial-and-error process development with intelligent computational modeling and simulation. By integrating advanced modeling, machine learning and real-world manufacturing data, the platform aims to reduce development timelines and improve process robustness across viral and non-viral gene therapy production.
The ARPA-H project will support validation of BioCurie’s platform in collaboration with leading partners, including a consortium of gene therapy leaders across academia and industry, including Caring Cross, St. Jude Children's Research Hospital, and Center for Breakthrough Medicines.
Established in 2022, ARPA-H is an independent federal research funding agency within the U.S. Department of Health and Human Services, that supports transformative biomedical and health breakthroughs.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!